Welcome to our dedicated page for Mereo Biopharma news (Ticker: MREO), a resource for investors and traders seeking the latest updates and insights on Mereo Biopharma stock.
Mereo Biopharma Group plc (MREO) is a clinical-stage biopharmaceutical leader developing innovative treatments for rare diseases. This dedicated news hub provides investors and industry professionals with timely updates on the company's clinical progress, strategic partnerships, and regulatory developments.
Our curated collection features official press releases and verified news covering critical milestones including clinical trial results, regulatory submissions, and strategic collaborations. Track updates across Mereo's pipeline targeting conditions like osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease.
All content undergoes rigorous verification to ensure accuracy and relevance. For comprehensive tracking of Mereo's progress in rare disease therapeutics, bookmark this page for direct access to primary source materials and expert analysis of corporate developments.
Mereo BioPharma Group (MREO) has entered a collaboration with Ultragenyx Pharmaceutical for the development of setrusumab, a monoclonal antibody for osteogenesis imperfecta (OI). Mereo will retain commercial rights in Europe, while Ultragenyx will lead global development and commercialization in other regions. Mereo will receive $50 million upfront and could earn up to $254 million in milestone payments. Setrusumab aims to be the first approved therapy for OI, which affects thousands without existing treatment options. The partnership is expected to focus on pediatric development starting in 2021.
Mereo BioPharma Group plc (NASDAQ: MREO) announced the cancellation of its Ordinary Shares trading on AIM, effective December 18, 2020. The last trading day on AIM will be December 17, 2020. Mereo will continue to list its American Depositary Shares (ADSs) on Nasdaq. Additionally, the company issued warrants to Silicon Valley Bank and Kreos Capital, allowing them to subscribe for 621,954 ordinary shares at $0.4144 per share. Mereo has also repaid a loan to the Lenders in full.
Mereo BioPharma Group plc (NASDAQ: MREO) announced the appointment of Dr. Suba Krishnan as Senior Vice President of Clinical Development, effective December 7, 2020. Dr. Krishnan brings over 20 years of experience in immuno-oncology, previously serving as Global Program Head at Genmab. Mereo's CEO, Dr. Denise Scots-Knight, expressed confidence in Dr. Krishnan's expertise aiding the advancement of their lead candidate, etigilimab. Mereo is progressing late-stage clinical trials for etigilimab and other therapeutic candidates in oncology and rare diseases.
Mereo BioPharma Group plc (NASDAQ: MREO) will host a virtual R&D day on November 24, 2020, to discuss its key pipeline programs. The event will focus on etigilimab (Anti-TIGIT) for solid tumors and alvelestat for alpha-1 antitrypsin deficiency and COVID-19 respiratory disease. Key opinion leaders from renowned institutions will present insights into the etigilimab development program. A live audio webcast will be available on the company’s website and an archived replay will follow. This initiative aims to enhance stakeholder understanding of Mereo's innovative therapeutic developments.
Mereo BioPharma Group, a clinical stage biopharmaceutical company, announced that CEO Dr. Denise Scots-Knight will present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 11:20 am ET. Investors can access a live audio webcast via the company’s website, with an archived version available for two weeks after the event. Mereo focuses on oncology and rare diseases, with products like etigilimab and setrusumab currently in various clinical trials. Forward-looking statements in the announcement caution investors about potential risks and uncertainties.
Mereo BioPharma Group plc (NASDAQ: MREO) announces the appointment of Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President of Regulatory Affairs. Fox, a CPA with over 18 years of experience, replaces interim CFO Michael Wyzga, while Petersen brings 25 years of regulatory expertise in biopharmaceuticals. Their appointments come as Mereo anticipates significant milestones in its pipeline, including a Phase 1b/2 study for its anti-TIGIT antibody, etigilimab, set to begin soon. Both bring valuable skills to strengthen Mereo's leadership.
Mereo BioPharma Group plc (NASDAQ: MREO) announced FDA clearance for its IND application to initiate a Phase 1b/2 study of etigilimab, a novel anti-TIGIT monoclonal antibody, in Q4 2020. The study will evaluate etigilimab with anti-PD-1 in 100 patients across various tumor types. Results from prior studies indicated no dose-limiting toxicities, with some patients achieving partial responses. Mereo plans a virtual R&D day in November 2020 to discuss the etigilimab program and its rare disease pipeline.
Mereo BioPharma Group plc (NASDAQ: MREO) reported its interim financial results for the first half of 2020, highlighting a successful $70 million PIPE financing, enhancing its cash resources to £56.8 million. The company is on track to start its Phase 1b/2 study for etigilimab (Anti-TIGIT) in Q4 2020 and has resumed enrollment in the Phase 2 study of alvelestat for Alpha-1 Antitrypsin Deficiency. Recent advancements include initiating a Phase 1b/2 clinical trial for alvelestat in COVID-19 patients and ongoing partnering discussions for its clinical-stage programs.
Mereo BioPharma Group plc (NASDAQ: MREO) reported interim financial results for the six months ended June 30, 2020, focusing on oncology and rare diseases. The company successfully completed a $70 million PIPE financing and has cash resources of £56.8 million, ensuring a runway into early 2022. They aim to initiate a Phase 1b/2 study of etigilimab in Q4 2020 and have resumed enrollment for alvelestat's Phase 2 study in Alpha-1 Antitrypsin Deficiency. Partnering discussions for setrusumab and other programs are ongoing.
Mereo BioPharma Group has received Rare Pediatric Disease designation from the FDA for its treatment setrusumab, aimed at osteogenesis imperfecta (OI), a rare genetic disorder without approved therapies. Setrusumab is a monoclonal antibody that inhibits sclerostin to promote bone formation. In clinical studies, it showed promising results in bone-building and fracture reduction. If a Biologics License Application is approved, Mereo may obtain a priority review voucher from the FDA, potentially facilitating future drug applications.
FAQ
What is the current stock price of Mereo Biopharma (MREO)?
What is the market cap of Mereo Biopharma (MREO)?
